Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Enovis Corporation
ENOV
NYSE·Healthcare·Medical - Devices·Mkt cap $1.2B
$22.50
▲ +12.28%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$19.14 - $36.82
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 40.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Established DJO brand with strong recognition among healthcare professionals
- Comprehensive product portfolio addressing multiple musculoskeletal conditions
- Diversified distribution network spanning direct, retail, and professional channels
- Integrated manufacturing and supply chain capabilities
- Long-standing relationships with orthopedic specialists and healthcare systems
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Rising prevalence of musculoskeletal disorders due to aging populations
Value
Deep value opportunity - significant discount to Industrial Machinery peers
Momentum
Weak
-11.5% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ENOV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of $0.89 vs $0.82 consensus (+8.5% surprise). Revenue of $589.2M vs $572.0M expected (+3.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+8.5%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+23%
+8%
+7%
+9%
+3%
+5%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$525.2M
$505.2M
$561.0M
$558.8M
$564.5M
$548.9M
$575.8M
$589.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1.5%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$36.00
▲ +60.0% vs $22.50
Latest: BTIG · May 22, 2026
1 analyst covering